Bioventus's total assets for Q1 2026 were $650.54M, a decrease of -4.83% from the previous quarter. BVS total liabilities were $416.27M for the fiscal quarter, a -8.53% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.